Article Menu
Need Help?
No Article Versions Notes Found
Cite
Hogg, D.; Monzon, J.G.; Ernst, S.; Song, X.; McWhirter, E.; Savage, K.J.; Skinn, B.; Romeyer, F.; Smylie, M. Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Curr. Oncol. 2020, 27, 204-214. https://doi.org/10.3747/co.27.5985
Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage KJ, Skinn B, Romeyer F, Smylie M. Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Current Oncology. 2020; 27(4):204-214. https://doi.org/10.3747/co.27.5985
Chicago/Turabian StyleHogg, D., J.G. Monzon, S. Ernst, X. Song, E. McWhirter, K.J. Savage, B. Skinn, F. Romeyer, and M. Smylie. 2020. "Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma" Current Oncology 27, no. 4: 204-214. https://doi.org/10.3747/co.27.5985
APA StyleHogg, D., Monzon, J. G., Ernst, S., Song, X., McWhirter, E., Savage, K. J., Skinn, B., Romeyer, F., & Smylie, M. (2020). Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Current Oncology, 27(4), 204-214. https://doi.org/10.3747/co.27.5985
